Targeted Therapy for Advanced Thyroid Cancer
Written by John P. Sabra, MD FACS
Updated May 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
For most patients with thyroid cancer, surgery and sometimes radioactive iodine are the complete treatment. For a smaller group with rare, aggressive, or metastatic disease, a new generation of precision drugs has changed what treatment looks like and what outcomes are possible.
This article is for patients who have been told their thyroid cancer is advanced, metastatic, radioactive iodine-refractory, or of a rare aggressive subtype such as anaplastic thyroid cancer or medullary thyroid cancer. It is also relevant for patients who want to understand why genetic testing of thyroid tumors has become a meaningful part of modern treatment.
What Targeted Therapy Is
Targeted therapy refers to drugs designed to interfere with specific molecular changes that drive cancer cell growth. Unlike conventional chemotherapy, which attacks all rapidly dividing cells broadly, targeted drugs block a particular protein, enzyme, or signaling pathway that a specific cancer depends on. The result — when a match exists between the drug and the mutation driving the cancer — can be dramatic tumor shrinkage with a more manageable side effect profile than traditional chemotherapy.
For targeted therapy to work, the cancer must carry the specific mutation the drug targets. This is why tumor genetic profiling matters. Knowing your tumor’s molecular fingerprint is the prerequisite for accessing the most effective available treatments.
The Mutations That Matter Most in Thyroid Cancer
| Mutation | Cancer Types | Targeted Drug(s) | What It Means Practically |
|---|---|---|---|
| BRAF V600E | Aggressive papillary thyroid cancer, anaplastic thyroid cancer | Dabrafenib + trametinib | Most common actionable mutation in aggressive papillary and anaplastic thyroid cancer. FDA-approved combination therapy with meaningful response rates. |
| RET fusion / RET mutation | Papillary thyroid cancer, medullary thyroid cancer | Selpercatinib, pralsetinib | Highly effective RET-targeted drugs have changed the treatment landscape for progressive or metastatic medullary thyroid cancer. |
| NTRK fusion | Papillary thyroid cancer (rare) | Larotrectinib, entrectinib | Rare but highly actionable. Tumor-agnostic FDA approval means these drugs are available for any cancer with NTRK fusions. |
| RAS mutation | Follicular thyroid cancer, poorly differentiated thyroid cancer | Under active investigation | No specific FDA approval yet, but relevant for clinical trial eligibility. |
Anaplastic Thyroid Cancer: The Most Urgent Case for Genetic Testing
Anaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer type. The identification of BRAF V600E mutations in approximately 40% of anaplastic thyroid cancers has changed the picture significantly. FDA-approved combination therapy with dabrafenib and trametinib has produced meaningful responses in BRAF-mutated ATC patients, with some patients achieving durable remission.
For any patient diagnosed with anaplastic thyroid cancer, BRAF mutation testing is not optional. It should be performed immediately and in parallel with other workup, because treatment timing in ATC is urgent and knowing the mutation status determines whether the most effective available treatment is accessible.
Medullary thyroid cancer (MTC) does not respond to radioactive iodine. Nearly all hereditary MTC and a significant portion of sporadic MTC are driven by RET mutations. Two highly effective RET-targeted drugs — selpercatinib and pralsetinib — have changed the treatment landscape for progressive or metastatic MTC. Any patient with MTC should have RET mutation testing performed. Patients with hereditary MTC should also pursue germline RET testing to identify family members at risk.
How Tumor Genetic Profiling Works
Tumor genetic profiling involves testing tissue from the cancer itself for a panel of known mutations and gene fusions. The tissue is typically from the surgical specimen or a prior biopsy. Results typically return within two to three weeks and are reviewed to determine which, if any, targeted therapies are applicable.
Major cancer centers have multidisciplinary tumor boards that review complex cases including molecular profiling results of advanced thyroid cancer patients. If you have advanced or refractory thyroid cancer and your care is being managed at a community center without access to this level of review, asking about referral to a thyroid cancer center with dedicated oncology expertise is an appropriate and important step.
The Bottom Line
Targeted therapy has meaningfully extended what is possible for patients with advanced, aggressive, and treatment-refractory thyroid cancers. But accessing these treatments requires knowing your tumor’s molecular profile, being cared for by physicians who follow this literature, and in many cases being seen at a center with multidisciplinary thyroid oncology expertise. If you have been diagnosed with an aggressive or advanced thyroid cancer, ask specifically whether molecular profiling of your tumor has been performed.
References
- Haugen BR, et al. 2015 ATA Management Guidelines for Thyroid Nodules and DTC. Thyroid. 2016.
- American Thyroid Association — Thyroid Cancer.
- National Cancer Institute — Thyroid Cancer Treatment.
This article was written by John P. Sabra, MD FACS and is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. Treatment decisions for advanced thyroid cancer require individualized evaluation by a multidisciplinary team with expertise in thyroid oncology.
More from the Advanced Thyroid Care series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →